RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Marcus Tius to Anticarcinogenic Agents

This is a "connection" page, showing publications Marcus Tius has written about Anticarcinogenic Agents.
Connection Strength

0.088
  1. Biswas DK, Mhashilkar AM, Ewaniuk DS, Pezza JA, Oh LM, Kannangara GS, Tius MA, Pardee AB. Inhibition of HIV-1 replication by combination of a novel inhibitor of TNF-alpha with AZT. J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Aug 15; 18(5):426-34.
    View in: PubMed
    Score: 0.034
  2. Komori A, Okabe S, Suganuma M, Kerr MA, Busch-Petersen J, Oh LM, Zhuo J, Kannangara GS, Zou X, Tius MA, Fujiki H. Anti-tumor promoting activity of canventol and its synthetic analogs through inhibition of protein isoprenylation. Jpn J Cancer Res. 1996 Sep; 87(9):875-81.
    View in: PubMed
    Score: 0.030
  3. Komori A, Suganuma M, Okabe S, Zou X, Tius MA, Fujiki H. Canventol inhibits tumor promotion in CD-1 mouse skin through inhibition of tumor necrosis factor alpha release and of protein isoprenylation. Cancer Res. 1993 Aug 01; 53(15):3462-4.
    View in: PubMed
    Score: 0.024
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support